Clinical Trial Update: Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating the combination of melphalan and bortezomib given before autologous stem cell transplant in multiple myeloma; the study was terminate…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Smoldering Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)
• Melphalan (Melphalan)

Snippet

Sponsor: University of Colorado, Denver | Conditions: Plasma Cell Myeloma, Plasmacytosis | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2015-03-09